Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

BrUOG 390: Neoadjuvant Treatment With Talazoparib for Women With Newly Diagnosed, Advanced Ovarian Cancer Associated With a Mutation in BRCA1 or BRCA2 (mBRCA)

NCT04598321 is registered in ClinicalTrials.gov with Brown University as lead sponsor.

NCT NCT04598321
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04598321 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
BrUOG 390: Neoadjuvant Treatment With Talazoparib for Women With Newly Diagnosed, Advanced Ovarian Cancer Associated With a Mutation in BRCA1 or BRCA2 (mBRCA)
Lead sponsor
Brown University
Phase
Phase 1
Overall status
Terminated
Start date
March 29, 2021
Completion date
December 6, 2022
Enrollment
1 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

brca1 mutation, brca2 mutation, fallopian tube cancer, high grade serous carcinoma, ovarian cancer